Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 4666 to 4680 of 7691 results

  1. Further research is needed on the impact of faecal calprotectin testing on clinical decision-making when added to current practice. This includes research into optimal cut-off values for tests and the investigation of repeat testing strategies in people with intermediate levels of faecal calprotectin. Development of a consistent definition for the 'intermediate range' is encouraged.

    Recommendation ID DG11/2 Question Further research is needed on the impact of faecal calprotectin testing on clinical decision-making when

    Research recommendation
    Published
    9 June 2015

  2. Further research is needed on the use and clinical utility of faecal calprotectin testing, and support pathways for the long-term management of these conditions in the community should be developed.

    Recommendation ID DG11/1 Question Further research is needed on the use and clinical utility of faecal calprotectin testing, and support

    Research recommendation
    Published
    9 June 2015

  3. Further research is needed to understand the effect of having the additional information provided by the adjunctive colposcopy technologies on anxiety for people having a colposcopy, when this information is shown to a person during the examination.

    Recommendation ID DG32/3 Question Further research is needed to understand the effect of having the additional information provided by

    Research recommendation
    Published
    21 November 2018

  4. Further research is recommended on alternative postpartum testing strategies that do not include cord blood typing of all babies born to rhesus-D (D) negative women.

    Recommendation ID DG25/1 Question Further research is recommended on alternative postpartum testing strategies that do not include cord

    Research recommendation
    Published
    10 February 2017

  5. Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER, IDKmonitor and Promonitor) in people whose Crohn's disease is losing response to a TNF-alpha inhibitor. This could be through a prospective study, for local audit, or for submission to a registry. (The IBD Registry is being adapted to receive data on TNF-alpha inhibitor levels and antibodies against TNF-alpha inhibitors).

    Recommendation ID DG22/2 Question Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER

    Research recommendation
    Published
    21 March 2016

  6. Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER, IDKmonitor and Promonitor) to monitor TNF-alpha-inhibitor levels and antibodies to a TNF-alpha inhibitor in people with Crohn's disease whose disease responds to treatment with TNF-alpha inhibitors. This should be evaluated using prospective studies.

    Recommendation ID DG22/3 Question Further research is recommended on clinical outcomes associated with using the ELISA kits (LISA-TRACKER

    Research recommendation
    Published
    21 March 2016

  7. Further research is recommended on how using sex-specific 99th percentile thresholds affects treatment decisions and clinical outcomes for men and women.

    Recommendation ID DG40/2 Question Further research is recommended on how using sex-specific 99th percentile thresholds affects treatment

    Research recommendation
    Published
    26 October 2020

  8. Further research is recommended on patient acceptability of using virtual chromoendoscopy for real-time assessment of diminutive polyps compared with assessment using histopathology

    Recommendation ID DG28/1 Question Further research is recommended on patient acceptability of using virtual chromoendoscopy for real-time

    Research recommendation
    Published
    12 October 2018

  9. Further research is recommended on resource use and clinical effects associated with using the xTAG Gastrointestinal Pathogen Panel, the FilmArray GI Panel and the Faecal Pathogens B assay.

    Recommendation ID DG26/1 Question Further research is recommended on resource use and clinical effects associated with using the xTAG Gastrointestinal

    Research recommendation
    Published
    17 February 2017

  10. Further research is recommended on: The accuracy of EarlyCDT Lung, and the validity of the risk models used to combine EarlyCDT Lung results with the Brock and the Herder risk models. The impact of EarlyCDT Lung on clinical management decisions. A large retrospective audit is recommended to: Understand how patient and nodule characteristics impact on malignancy prevalence and disease progression. Understand current practice regarding clinical management of people with intermediate-risk lung nodules. Determine the clinical consequences of CT surveillance, including the likelihood of disease progression during CT surveillance. Determine the likelihood and impact of unnecessary biopsy or resection of indolent and benign nodules If existing data on these points is limited or not routinely collected, a prospective data collection should be undertaken to obtain it.

    Recommendation ID DG46/01 Question Further research is recommended on: The accuracy of EarlyCDT Lung, and the validity of the risk models

    Research recommendation
    Published
    24 March 2022

  11. Further research is recommended on the diagnostic performance of the TriageTrue high-sensitivity troponin test using samples at point of care.

    Recommendation ID DG40/1 Question Further research is recommended on the diagnostic performance of the TriageTrue high-sensitivity troponin

    Research recommendation
    Published
    26 October 2020

  12. Further research is recommended on:• the impact of LiverMultiScan test results on decisions about care, such as the decision to do a liver biopsy, or on adherence to lifestyle interventions (see section 3.5 )• the test accuracy of LiverMultiScan compared with biopsy, or the prognostic ability of LiverMultiScan to predict clinical outcomes (see section 3.19 ).

    Recommendation ID DG50/01 Question Further research is recommended on:• the impact of LiverMultiScan test results on decisions about care

    Research recommendation
    Published
    3 February 2023

  13. Further research is recommended on the use of repeat PlGF-based testing (Triage PlGF test and Elecsys immunoassay sFlt-1/PlGF ratio), with standard clinical assessment, in women presenting with suspected pre-eclampsia between 20 weeks and 34 weeks plus 6 days of gestation, who have had a negative PlGF-based test result (Triage PlGF test result of 100 picograms/ml or more; Elecsys immunoassay sFlt 1/PlGF ratio of less than 38) that was used to rule-out pre-eclampsia. This should include:- exploration of the different scenarios in which repeat testing may be indicated- the appropriate intervals between PlGF-based tests- the diagnostic accuracy of PlGF-based testing in women with suspected pre-eclampsia who have previously had 1 or more negative PlGF-based test results.

    Recommendation ID DG23/1 Question Further research is recommended on the use of repeat PlGF-based testing (Triage PlGF test and Elecsys

    Research recommendation
    Published
    22 June 2016

  14. Further research is recommended on:• the impact of magnetic resonance elastography (MRE) test results on decisions about care, such as the decision to do a liver biopsy, or on adherence to lifestyle interventions (see section 3.5 )• the test accuracy of MRE to assess the level of fibrosis or presence of cirrhosis compared with biopsy at thresholds specified by the company, or the prognostic ability of MRE to predict clinical outcomes (see section 3.20 ).

    Recommendation ID DG50/02 Question Further research is recommended on:• the impact of magnetic resonance elastography (MRE) test results

    Research recommendation
    Published
    3 February 2023

  15. Further data collection and research are recommended to understand how SeHCAT (tauroselcholic [75 selenium] acid) test results affect clinical decision making.

    Recommendation ID DG44/01 Question Further data collection and research are recommended to understand how SeHCAT (tauroselcholic [75 selenium]

    Research recommendation
    Published
    16 December 2021